Atlas Trials

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Clinical trial NCT00381550 · COMPLETED

Trial details

NCT number
NCT00381550
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Accelerated Phase Chronic Myelogenous LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaChronic Eosinophilic LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaPhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPolycythemia VeraPrimary MyelofibrosisRelapsing Chronic Myelogenous Leukemia
Start date
2006-08-01
Primary completion
2011-03-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.